Multiple glucagon-like peptide-1 (GLP-1) agonist medications, created for the treatment of type 2 diabetes mellitus, are now labeled for the treatment of obesity
Lpez-de-Ipia, P
One is a natural metabolic modulator, while the other alters hormonal responses to food and appetite
All rights are reserved under the copyright laws of the United States of America
Third, when Congress addressed obesity treatment in the FY 2017 National Defense Authorization Act, it did so by authorizing programs for all covered beneficiaries, not by singling out Prime and Select
The first SSRI, the first statin, the first PD-1 inhibitor, each one shocked the field with effect sizes that reset expectations, then, over the following decade, slowly revealed the limitations that the next generation was built to fix